Infective endocarditis (IE) is an infection of the endocardial surfaces of the heart, which includes 1 or more heart valves. The incidence of infective endocarditis hospitalization in the United States is estimated at 12.7 per 100,000, annually. A majority of the patients (57.7%) were male and more than a third were at the age of 70 and older. Several risk factors predispose patients to IE, such as structural heart disease (valvular disease or congenital heart disease), prosthetic heart valves, indwelling cardiovascular device, an intravascular catheter, chronic hemodialysis, human immunodeficiency virus infection, diabetes, or history of infective endocarditis. Other risk factors include male older than 60 years, male gender, intravenous (IV) drug use, poor dentition, or dental infection. Infective endocarditis may present as acute or subacute infection. Acute infections present as a rapidly progressive disease with high fevers, rigors, and sepsis. On the other hand, subacute bacterial endocarditis diagnosis is often delayed and presents as non-specific symptoms such as weight loss, fatigue, dyspnea over several weeks to months. There are several differences between subacute bacterial endocarditis and acute bacterial endocarditis. Most cases of subacute bacterial endocarditis are caused by penicillin sensitive Streptococcus viridans, while Staphylococcus aureus causes most cases of acute bacterial endocarditis. Subacute bacterial endocarditis mostly happens in pre-existing heart disease while acute bacterial endocarditis mostly happens in healthy hearts. After treatment, subacute bacterial endocarditis rarely leads to severe cardiac damage; however, most patients who survive acute bacterial endocarditis often die of cardiac failure within weeks or months.
As the incidence of infective endocarditis continues to rise in the United States, healthcare providers must make appropriate decisions regarding antibiotic prophylaxis to prevent further complications. Antibiotic prophylaxis before procedures, especially dental procedures, used to be widely utilized to prevent infective endocarditis despite a lack of established evidence to support this practice. In guidelines published by the American Heart Association (AHA) in 2007, the recommended indications to use antibiotics for endocarditis prophylaxis were significantly restricted. There were several reasons for this change. Firstly, infective endocarditis was more likely to occur with everyday activities such as teeth brushing and flossing rather than with a single medical or dental procedure. Secondly, it was felt that prophylaxis with antibiotics for dental procedures prevented very few IE cases. The cost of antibiotic therapy and the risk of adverse events and risk of promoting antibiotic resistance significantly outweighed the benefit of such prophylaxis. Thirdly, consistently good oral hygiene is considered more beneficial in preventing IE than a single dose of antibiotics.
The function of prophylactic therapy for subacute bacterial endocarditis are the following:
Infective endocarditis is fatal if untreated or unrecognized. It causes significant morbidity and mortality, despite present-day advances in antimicrobial therapy and surgical treatment. As a result, the prevention of infective endocarditis is necessary. Some animal studies have shown antibiotics prophylaxis to prevent infective endocarditis, but the data in humans is still lacking. Current guidelines in the United States still recommend the use of antimicrobial prophylaxis for patients undergoing several procedures who are at risk for infective endocarditis.
The American Heart Association currently recommends antibiotic prophylaxis only in patients with the following high-risk cardiac conditions:
Patients with these high-risk conditions should receive antibiotics for the following procedures:
Prophylaxis against IE is not recommended in patients who are at risk of IE for other nondental procedures, for example, TEE, esophagogastroduodenoscopy, colonoscopy, or cystoscopy, in the absence of active infection.
Patient's ability to tolerate oral medication are influenced by medication allergies, and by the most likely pathogen. For dental and respiratory procedures, the most common bacteria are the various Streptococcus viridans species. The recommended prophylactic antibiotic is amoxicillin 2 grams orally 1 hour before the procedure. If the patient needs intravenous (IV) medication, ampicillin or ceftriaxone may be used. Cephalexin, clindamycin, or azithromycin may be used in patients with a penicillin allergy. There is new penicillin resistance of the Streptococcus viridian. The prescribing physician must consider the resistance in his/her area of practice when prescribing the appropriate antibiotic. In cases where Staphylococcus aureus is suspected, antistaphylococcal penicillin or vancomycin is recommended.
Currently, there is no indication for dental, gastrointestinal, or genitourinary procedural prophylaxis for patients with implantable cardiovascular devices. However, prophylaxis with an anti-staphylococcal antibiotic is indicated at the time of cardiovascular device implantation and any subsequent manipulation of the surgically created device pocket.
For patients who have undergone coronary artery bypass graft surgery, antibiotic prophylaxis is not needed for dental procedures, as there is no increased risk of long-term infection. Similarly, for patients with coronary artery stents, antibiotic prophylaxis is not needed for dental procedures.
Subacute IE is a lethal disorder if not treated. Healthcare professionals including the nurse practitioner, dentist, pharmacist, primary care provider, an internist, and the cardiologist should be familiar with the latest ACA and AHA guidelines on prophylaxis of patients at risk for IE. Prophylaxis against IE is not recommended in patients who are at risk of IE for other nondental procedures, for example, TEE, esophagogastroduodenoscopy, colonoscopy, or cystoscopy, in the absence of active infection. For patients who have undergone coronary artery bypass graft surgery, antibiotic prophylaxis is not needed for dental procedures, as there is no increased risk of long-term infection. Similarly, for patients with coronary artery stents, antibiotic prophylaxis is not needed for dental procedures.
|||Bor DH,Woolhandler S,Nardin R,Brusch J,Himmelstein DU, Infective endocarditis in the U.S., 1998-2009: a nationwide study. PloS one. 2013 [PubMed PMID: 23527296]|
|||Habib G,Lancellotti P,Antunes MJ,Bongiorni MG,Casalta JP,Del Zotti F,Dulgheru R,El Khoury G,Erba PA,Iung B,Miro JM,Mulder BJ,Plonska-Gosciniak E,Price S,Roos-Hesselink J,Snygg-Martin U,Thuny F,Tornos Mas P,Vilacosta I,Zamorano JL, 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). European heart journal. 2015 Nov 21 [PubMed PMID: 26320109]|
|||HAMBURGER M, Acute and subacute bacterial endocarditis. Archives of internal medicine. 1963 Jul [PubMed PMID: 13952298]|
|||Dajani AS,Taubert KA,Wilson W,Bolger AF,Bayer A,Ferrieri P,Gewitz MH,Shulman ST,Nouri S,Newburger JW,Hutto C,Pallasch TJ,Gage TW,Levison ME,Peter G,Zuccaro G Jr, Prevention of bacterial endocarditis: recommendations by the American Heart Association. Journal of the American Dental Association (1939). 1997 Aug [PubMed PMID: 9260427]|
|||Weddell JA,Clark JC, Current guidelines and dental applications for the SBE prophylaxis. Journal (Indiana Dental Association). 1987 May-Jun; [PubMed PMID: 2957474]|
|||Thornhill MH,Dayer MJ,Forde JM,Corey GR,Chu VH,Couper DJ,Lockhart PB, Impact of the NICE guideline recommending cessation of antibiotic prophylaxis for prevention of infective endocarditis: before and after study. BMJ (Clinical research ed.). 2011 May 3; [PubMed PMID: 21540258]|
|||Verhagen DW,Vedder AC,Speelman P,van der Meer JT, Antimicrobial treatment of infective endocarditis caused by viridans streptococci highly susceptible to penicillin: historic overview and future considerations. The Journal of antimicrobial chemotherapy. 2006 May; [PubMed PMID: 16549513]|
|||Sàndor GK,Carmichael RP,Vasilakos JS, Revised American Heart Association guidelines for the prevention of bacterial endocarditis: highlights of specific changes for the dental profession. Journal (Canadian Dental Association). 1998 Feb; [PubMed PMID: 9509818]|
|||Anupama P,Gopalakrishnan NS, Infective endocarditis, the conundrum of antibiotic prophylaxis. Indian journal of dental research : official publication of Indian Society for Dental Research. 1995 Jul-Sep; [PubMed PMID: 9495112]|